Weekly Digest – June 2025 Weekly Digest – June 2025 03 June 2025: European Commission approves ADCETRIS (Brentuximab vedotin) for the treatment of adult patients with newly diagnosed stage IIb/III/IV hodgkin lymphoma in combination with ECADD Takeda’s ADCETRIS-based regimen BrECADD […]
Weekly Digest – June 2025 Weekly Digest – June 2025 02 June 2025: Lilly presents first clinical data for its investigational, next-generation FRα targeting ADC in platinum-resistant ovarian cancer at the 2025 ASCO Annual Meeting Eli Lilly’s FRα-targeting ADC (LY4170156) […]
Weekly Digest – June 2025 Weekly Digest – June 2025 03 June 2025: Avenzo Therapeutics initiates Phase 1/2 clinical study of AVZO-1418, a potential best-in-class, novel EGFR/HER3 bispecific antibody drug conjugate Avenzo Therapeutics has initiated a Phase 1/2 clinical trial for […]
Weekly Digest – June 2025 Weekly Digest – June 2025 31 May 2025: Trodelvy plus Keytruda reduces risk of disease progression or death by 35% versus Keytruda and chemotherapy in first-line PD-L1+ metastatic triple-negative breast cancer Gilead reported that Trodelvy […]
Weekly Digest – June 2025 Weekly Digest – June 2025 02 June 2025: ENHERTU plus Pertuzumab reduced the risk of disease progression or death by 44% versus THP as first-line therapy in patients with HER2 positive metastatic breast cancer in […]
Weekly Digest – June 2025 Weekly Digest – June 2025 05 June 2025: LigaChem Biosciences inks dual antibody licensing deals with NovaRock for ADC drug development LigaChem Biosciences has signed two global licensing agreements with NovaRock Biotherapeutics to acquire exclusive […]
